Downregulation of CD73 associates with T cell exhaustion in AML patients

BACKGROUND: Successful treatment for acute myeloid leukemia (AML) remains challenging. Inhibiting immune checkpoint to enhance anti-tumor response is an attractive strategy for effective leukemia therapeutics. CD73 is a recently recognized immune checkpoint mediator that is highly expressed on tumor...

詳細記述

保存先:
書誌詳細
出版年:J Hematol Oncol
主要な著者: Kong, Yaxian, Jia, Bei, Zhao, Chenchen, Claxton, David F., Sharma, Arati, Annageldiyev, Charyguly, Fotos, Joseph S., Zeng, Hui, Paulson, Robert F., Prabhu, K. Sandeep, Zheng, Hong
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2019
主題:
Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6480867/
https://ncbi.nlm.nih.gov/pubmed/31014364
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-019-0728-3
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料